ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: In studies on chronic myeloid leukemia (CML) cell lines K562 and LAMA-84, as well as imatinib-resistant cultures, elacridar at a concentration of 0.25 μM effectively inhibited ABC transporter activity and led to a 5- to 10-fold increase in sensitivity to imatinib, as confirmed by flow cytometry [62].